Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3047% above fair value
$2.38−0.13 (-4.99%)
Close on Nov 11, 2026Market cap $365.52MP/E –Yield –
Editas Medicine price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Editas Medicine's price to sales ratio was 5.0× on Nov 11, 2026, against 4.8× a year earlier. Over the last 5 years it ranged from 1.7× to 74.1×, with a median of 7.8×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 5.0× | +0.8 |
| 2025 | Dec 31, 2025 | 4.1× | +2.4 |
| 2024 | Dec 31, 2024 | 1.7× | −31.9 |
| 2023 | Dec 29, 2023 | 33.6× | +9.8 |
| 2022 | Dec 30, 2022 | 23.8× | −50.3 |
| 2021 | Dec 31, 2021 | 74.1× | +26.5 |
| 2020 | Dec 31, 2020 | 47.6× | −57.7 |
| 2019 | Dec 31, 2019 | 105.3× | +68.6 |
| 2018 | Dec 31, 2018 | 36.7× | – |
See a number that looks wrong?